AGAP3 and Cryptococcal meningitis: Serum screening for cryptococcal antigen (CrAg) and subsequent prophylaxis for those who screen positive limits the burden of disease by preventing the progression from cryptococcal antigenemia to cryptococcal meningitis or death [1, 3].